Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval

MT Newswires Live

Jun 01

Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-K for the year ended Dec. 31, 2025, which includes the 2024 audit.

The company said it believes the audit is in its final stages of approval.

Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.

The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.

Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2640558259"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640558259\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640558259?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640558259","market":"nz","top_or_hot":-1,"title":"Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval","media":"MT Newswires Live","content":"<html><body><p> Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the year ended Dec. 31, 2025, which includes the 2024 audit.</p><p>The company said it believes the audit is in its final stages of approval.</p><p>Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.</p><p>The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.</p><p>Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGreenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-01 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the year ended Dec. 31, 2025, which includes the 2024 audit.</p><p>The company said it believes the audit is in its final stages of approval.</p><p>Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.</p><p>The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.</p><p>Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLSI","symbol_name":"Greenwich Lifesciences Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640558259","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640558259","pubTimestamp":1780310925,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Greenwich LifeSciences  said Monday its new auditor continues to audit the company's Form 10-K for the year ended Dec. 31, 2025, which includes the 2024 audit.The company said it believes the audit is in its final stages of approval.Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLSI":"Greenwich Lifesciences Inc","BK4139":"生物科技"},"translate_title":"Greenwich LifeSciences表示对2025年10-K表格备案的审计已进入批准的最后阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLSI":1},"content_text":"Greenwich LifeSciences (GLSI) said Monday its new auditor continues to audit the company's Form 10-K for the year ended Dec. 31, 2025, which includes the 2024 audit.The company said it believes the audit is in its final stages of approval.Greenwich LifeSciences said accounts payable adjustments were related to its ongoing global phase III clinical trial and an unexpectedly large increase in screening and patient enrollment in Europe during 2024 and 2025.The company does not believe the adjustments are material to it or its investors and that they do not change the company's fundamentals, it said.Greenwich LifeSciences said that the shift in expenses does not affect its cash balance or net cash used in operating activities. The company said it had a cash balance of $10.5 million as of March 31, which it said exceeded its 2025 net cash used in operating activities of around $9.9 million.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}